No more disparities among regions in Italy: recent approval of genomic test reimbursability for early breast cancer patients in the country

There are five BC gene-profiling tests commercially available namely Prosigna®(PAM50), Mammaprint®, Oncotype DX®, Breast Cancer Index®, and Endopredict®. The use of these tests emerge to be different among the various countries because of the disparity in clinical criterion of genomic test recommend...

Ausführliche Beschreibung